Amyris (NASDAQ:AMRS) initiated with Outperform rating and $8 (147% upside) price target at Oppenheimer. Shares up 8% premarket.
Bausch Health Companies (NYSE:BHC) upgraded to Overweight with a C$50.04 (30% upside) price target at JPMorgan. Shares up 2% premarket in the U.S.
Globus Medical (NYSE:GMED) upgraded to Overweight with a $63 (11% upside) at Wells Fargo. Shares up 1% premarket.
Healthcare Realty Trust (NYSE:HR) upgraded to Buy at Citigroup.
MEDNAX (NYSE:MD) upgraded to Buy with a $33 (23% upside) price target at Stifel. Shares up 1% premarket.
Shockwave Medical (NASDAQ:SWAV) upgraded to Overweight with a $49 (17% upside) price target at Wells Fargo. Shares up 3% premarket.
Merit Medical Systems (NASDAQ:MMSI) downgraded to Underweight with a $26 (13% downside risk) price target at Baird. Shares down 4% premarket.
Miragen Therapeutics (NASDAQ:MGEN) downgraded to Neutral with a $1 (45% upside) price target at Baird. Shares down 19% premarket on change in strategy and downsizing.
West Pharmaceutical Services (NYSE:WST) downgraded to Underperform with a $135 (8% downside risk) at BofA Merrill Lynch.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.